All In Biotech

Drug Trial Radar · NCT01281527

Paliperidone Palmitate Flexible Dosing in Schizophrenia

A 6-month, Open Label, Prospective, Multicenter, International, Exploratory Study of a Transition to Flexibly Dosed Paliperidone Palmitate in Patients With Schizophrenia Previously Unsuccessfully Treated With Oral or Long-acting Injectable Antipsychotics

Last checked: Nov 19, 2026Latest source record: Mar 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,044

Actual

Start

Nov 2010

Primary completion

Nov 2012

Study completion Nov 2013

Sponsor

Lead sponsor
Janssen-Cilag International NVJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 24, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study explores the tolerability, safety and efficacy (i.e. how well the drug works) of flexibly dosed paliperidone palmitate in the treatment of schizophrenia in patients previously unsuccessfully treated with other oral or long-acting injectable (LAI) (i.e. with a long duration of action) antipsychotics.

Conditions

  • Schizophrenia

Interventions

  • Paliperidone PalmitateDrug

    50 - 150 mg eq. every 30 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improved efficacy for non-acute patients transitioned due to lack of efficacy, as measured by the total PANSS score at endpoint versus baseline.Time frame: Baseline to 6 months or early discontinuation
  2. Improved efficacy for acute patients, as measured by the total PANSS score at endpoint versus baseline.Time frame: Baseline to 6 months or early discontinuation
  3. Maintained efficacy for non-acute patients transitioned for other reasons based on PANSS score at endpoint versus baseline.Time frame: Baseline to 6 months or early discontinuation

Locations

127 sites in 20 countries. Site status is shown where the registry gives one.

  • Site not named

    Salzburg, Austria

  • Site not named

    Brussels, Belgium

  • Site not named

    Dave, Belgium

  • Site not named

    Diest, Belgium

  • Site not named

    Kruishoutem, Belgium

  • Site not named

    Liège, Belgium

  • Site not named

    Melle, Belgium

  • Site not named

    Roeselare, Belgium

  • Site not named

    Sint-Denijs-Westrem, Belgium

  • Site not named

    Tournai, Belgium

  • Site not named

    Rijeka, Croatia

  • Site not named

    Zagreb, Croatia

  • Site not named

    Aalborg, Denmark

  • Site not named

    København V, Denmark

  • Site not named

    Randers, Denmark

  • Site not named

    Tallinn, Estonia

  • Site not named

    Bar-le-Duc, France

  • Site not named

    Bron, France

  • Site not named

    Clermont-Ferrand, France

  • Site not named

    Dax, France

  • Site not named

    Dijon, France

  • Site not named

    Dole, France

  • Site not named

    Lille, France

  • Site not named

    Limoges, France

  • Site not named

    Montpellier, France

  • Site not named

    Nîmes, France

  • Site not named

    Paris, France

  • Site not named

    Saint-Nazaire, France

  • Site not named

    Saint-Priest-en-Jarez, France

  • Site not named

    Strasbourg, France

  • Site not named

    Villejuif, France

  • Site not named

    Bad Saarow, Germany

  • Site not named

    Berlin, Germany

  • Site not named

    Bielefeld, Germany

  • Site not named

    Bochum, Germany

  • Site not named

    Butzbach, Germany

  • Site not named

    Dresden, Germany

  • Site not named

    Gelsenkirchen, Germany

  • Site not named

    Greifswald, Germany

  • Site not named

    Hamburg, Germany

Showing 40 of 127 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.